Report for the first quarter 2003

Report for the first quarter 2003 Biora AB (publ) April 25, 2003 1st Qtr 1st Qtr Full Year 2003 2002 2002 Net sales, SEK million 34.6 35.0 129.7 Operating result, SEK million 1.4 -1.0 -0.9 Net result, SEK million 1.4 -0.7 0.7 · On April 7, 2003, Straumann Holding AG announced a public offer to the shareholders and warrant holders of Biora AB. Biora´s Board of Directors unanimously recommends that Biora shareholders accept the cash offer of SEK 17 per ordinary share. · Sales during the first quarter 2003 amounted to SEK 34.6 million (compared to SEK 35.0 million for the first quarter 2002). · Significant negative impact on sales during the first quarter 2003 due to the decline in the U.S. dollar exchange rate compared to the first quarter 2002. · Net income during the first quarter 2003 was SEK 1.4 million (compared to a net loss of SEK 0.7 million for the first quarter 2002). · Net change in cash for the first quarter 2003 was SEK -4.2 million (compared to SEK -3.5 million for the first quarter 2002). Biora develops, manufactures and sells biotechnology-based products to dentists. Its principal product, Emdogain®Gel, which is approved for sale in Europe, North America and Japan among others, naturally regenerates the tooth-supporting structure that the tooth has lost due to periodontitis. Biora's shares are listed on the "O-list" of the Stockholm Stock Exchange in Sweden. For further information, please contact: Svante Lundell, CFO and Investor Relations, Biora, tel: +46 40-32 13 56 or +46 705 32 30 56 Donna Janson, President and CEO of Biora, tel: +46 40 32 12 28 http://www.biora.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/04/25/20030425BIT00880/wkr0001.doc The full report http://www.waymaker.net/bitonline/2003/04/25/20030425BIT00880/wkr0002.pdf The full report